ArticleJournal of Alzheimer's disease reports
Identification of novel serum biomarkers for Alzheimer's disease screened by phage display library of random peptides.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identification of Alzheimer's disease (AD) needs inexpensive, noninvasive novel biomarkers. autoimmunity plays a key role in the pathogenesis of AD. Objective: This study aims to screen innovative diagnostic biomarkers for AD from the perspective of autoantibodies. Methods: The study consisted of two screening phases and two validation phases. AD serum autoantibody-related biomarkers were discovered and validated using serum samples from four independent cohorts encompassing 241 participants, i.e., AD patients, healthy controls, and other dementia-related diseases. First, to identify biomarkers for AD, a phage displayed random peptide library (Ph.D.12) was applied to screen specific autoantibodies in a total of 71 serum samples from 39 AD patients and 32 healthy controls. After further screening by polypeptide microarray, Then, for validation, three peptides were analyzed in another two independent cohorts, which included AD patients, healthy controls, and other dementia-related diseases, Enzyme-linked immunosorbent assay (ELISA) was finally used to evaluate their sensitivity and specificity for AD diagnosis. Results: Our results show that both AD2024Val03, AD2024Val70, and AD2024Val72 showed a statistically significant ability to discriminate AD patients from controls and other dementia-related diseases. Additionally, combination of these three peptides, AD2024Val, could greatly improve the diagnostic performance (AUC is above 0.95, sensitivity ∼100%, specificity ∼79%). Conclusions: the peptides we identified could serve as promising blood biomarkers for AD clinical diagnosis, which also might provide new insights into the potential pathogenesis of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.